Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Agur
Anne Maria Reet Agur, Toronto CA
| Patent application number | Description | Published |
|---|---|---|
| 20100216106 | SYSTEM AND METHOD FOR LEARNING STRUCTURE USING ENVELOPES - The present invention discloses a method and system for enabling the learning of a portion of anatomy. The system of the present invention comprises a learner; an envelope worn by the learner, another person, or an animal; media to instruct the learner on anatomy; and an annotation tool enabling the learner to annotate the anatomy on the envelope. The present invention may be used for any part of human or non-human anatomy. | 08-26-2010 |
Enno E. Agur, Toronto CA
| Patent application number | Description | Published |
|---|---|---|
| 20100015544 | TONER PROCESS - The present disclosure provides toners and processes for preparing toner particles possessing excellent charging characteristics. The process includes forming a dispersion including at least one organic and/or organometallic charge control agent, and then combining that dispersion with an emulsion suitable for use in forming toner particles. | 01-21-2010 |
| 20100143839 | TONER PROCESS - The present disclosure provides processes for increasing the shelf life and stability of resin emulsions suitable for use in forming toner particles. In embodiments, the pH of the resin emulsion is monitored, and a base is added as needed to maintain the pH of the emulsion at from about 6.5 to about 8. Maintaining the pH at from about 6.5 to about 8 prevents the degradation of the resin in the emulsion, including its molecular weight. | 06-10-2010 |
| 20100297546 | TONER COMPOSITIONS - Toner particles are provided which may, in embodiments, include a core and a shell. In embodiments, charge control agents may be co-emulsified with a resin utilized to form a shell. The shell may prevent a crystalline resin in the core from migrating to the toner surface. Inclusion of the charge control agent in the shell itself may provide the resulting toner particles with desirable charge characteristics and sensitivity to relative humidity. | 11-25-2010 |
Zvia Agur, Tel Aviv IL
| Patent application number | Description | Published |
|---|---|---|
| 20080275684 | TREATMENT PROTOCOL GENERATION FOR DISEASES RELATED TO ANGIOGENESIS - A computer-implemented method for determining an optimal treatment protocol for a disease related to angiogenesis, comprising creating an angiogenesis model including pro-angiogenesis and anti-angiogenesis factors. Effective vessel density (EVD) is incorporated as a factor regulating switching on and switching off of at least one component in the angiogenesis model. Effects of vasculature maturation and mature vessels destabilization are incorporated. Pro-angiogenesis and anti-angiogenesis factors, which can influence changes in state of a tissue are selected. Effects of drugs in the pro-angiogenesis and anti-angiogenesis factors are incorporated. A plurality of treatment protocols in a protocol space is generated. A best treatment protocol based on a pre-determined criteria. | 11-06-2008 |
| 20100161301 | Techniques for Purposing a New Compound and for Re-Purposing a Drug - A method for repurposing a pharmaceutical compound. The method includes identifying a pharmaceutical compound, the pharmaceutical compound corresponding to a drug that has failed in clinical development or an approved drug. A mathematical model describing the physiological processes related to at least one disease and the effects of the pharmaceutical compound on the disease is created. The model is adjusted based upon information from preclinical or clinical trials. A new treatment protocol is suggested to salvage the failed drug or a new way to use an approved drug. The suggested treatment protocol is displayed. Systems and computer program products encompassing the above techniques are also disclosed. | 06-24-2010 |
| 20100235150 | THERAPEUTIC IMPLICATIONS OF DICKKOPF AFFECTING CANCER STEM CELL FATE - A method of determining a therapeutic regimen for the treatment of cancer with Dickkopf (Dkk) protein in which a mathematical model of differential equations describing the major signaling pathways involved in stem cell regulation is created and used to simulate signals from the cancer stem cell environment based upon administration of at least a single dose of Dkk in vitro and/or in vivo. A method of modulating cancer stem cells is also provided in which the stem cell computer model is simulates the effect of Dkk and performs a calibration test to determine a threshold value above which Dkk induces cell differentiation and a threshold value below which Dkk induces stem cell proliferation. | 09-16-2010 |